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ABSTRACT
Background. The EUropean REgistration of Cancer CAre
(EURECCA) consortium aims to investigate differences in
treatment and to improve cancer care through Europe. The
purpose of this study was to compare neo- and adjuvant
chemotherapy (ACT) and outcome after tumor resection
for pancreatic adenocarcinoma stage I and II in the EUR-
ECCA Pancreas consortium.
Methods. The eight, collaborating national, regional, and
single-center partners shared their anonymized dataset.
Patients diagnosed in 2012–2013 who underwent tumor
resection for pancreatic adenocarcinoma stage I and II were
investigated with respect to treatment and survival and
compared using uni- and multivariable logistic and Cox
regression analyses. All comparisons were performed
separately per registry type: national, regional, and single-
center registries.
Results. In total, 2052 patients were included. Stage II was
present in the majority of patients. The use of neo-ACT
was limited in most registries (range 2.8–15.5%) and was
only different between Belgium and The Netherlands after
adjustment for potential confounders. The use of ACT was
different between the registries (range 40.5–70.0%), even
after adjustment for potential confounders. Ninety-day
mortality was also different between the registries (range
0.9–13.6%). In multivariable analyses for overall survival,
differences were observed between the national and
regional registries. Furthermore, patients in ascending age
groups and patients with stage II showed a significant
worse overall survival.
Conclusions. This study provides a clear insight in clinical
practice in the EURECCA Pancreas consortium. The dif-
ferences observed in (neo-)ACT and outcome give us the
chance to further investigate the best practices and improve
outcome of pancreatic adenocarcinoma.
Pancreatic cancer (PC) is one of the few types of cancer
with increasing incidence and mortality rates.1 In 2017, the
number of annual deaths in the European Union due to PC
will exceed the number of death due to breast cancer.2
Resection is the only chance for prolonged survival;
unfortunately only 15–20% of PC patients are eligible for
resection due to advanced or metastatic disease at diag-
nosis.3 Tumor/node/metastases (TNM) stage I and II PC
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are generally considered eligible for resection.4 The
European Society of Medical Oncology (ESMO) guideli-
nes, during the study period and most recent, state that
patients with a borderline resectable or locally advanced
tumor should be treated with neoadjuvant chemotherapy
(neo-ACT) in clinical trials whenever possible and that
adjuvant chemotherapy (ACT) is considered as standard of
care after curative resection for PC.5,6 Recently, the
ESPAC-4 trial showed a survival benefit in patients treated
with adjuvant gemcitabine and capecitabine compared with
gemcitabine alone.7 Despite advances in (neo)-ACT, the
median survival for patients with an initial resectable tumor
is only 23.3 (range 12–54) months.8
Previous studies have reported variations in incidence,
mortality and survival in PC between countries.9–12 The
EUropean REgistration of Cancer CAre (EURECCA)
consortium, established by the European CanCer Organi-
sation (ECCO), aims to investigate differences in treatment
and to improve cancer care through Europe.13 International
comparisons of (neo-)ACT and outcome in surgically
treated patients with PC are sparse. Therefore, the purpose
of this study was to describe and compare (neo-)ACT and
outcome of patients who underwent tumor resection for
resectable (TNM stage I and II) pancreatic adenocarcinoma
in the EURECCA Pancreas consortium.
MATERIALS AND METHODS
Study Design and Data Preparation
This is an observational cohort study of eight partners
(registries) in the EURECCA Pancreas consortium [national:
Belgium (BE), The Netherlands (NL), Slovenia (SLO),
Ukraine (UA), and Bulgaria (BG); regional: Catalonia
(Spain) (CAT(E)) and Munich (Germany) (MU(D); and
single center: Milan (Italy) (MIL(I))] who shared their
anonymized dataset. Detailed description of the registries is
provided in Table S1 (Supplementary). The American Joint
Committee on Cancer and International Union Against
Cancer TNM 7th Edition classification were used to describe
stage.4,14 In case pathology TNM variables were not infor-
mative (missing or X), clinical TNM variables were used as
replacement. In case clinical TNM variables also were not
informative (missing or X), pathology TNM variables were
considered to be ‘‘0.’’ The 3rd edition of the International
Classification of Disease for Oncology was used for topo-
graphical and morphological (i.e., pathologic diagnosis)
coding.15 Age was categorized as\ 65 years, 65–75 years,
and[ 75 years. Overall survival (OS) was calculated from
date of surgery until date of death (event) or last follow-up
(censored). Ninety-day mortality was calculated to distin-
guish surgery-related from disease-related death.16
Patient Selection
All patients with pancreatic tumors (included codes:
C25.0–C25.9; excluded: C25.4), diagnosed in 2012–2013
(present in all registries), undergoing tumor resection, for
adenocarcinoma (included codes: 8140-8380, 8500-8585;
excluded: 8150-8158, 8240-8249), stage I and II were
included.15 Patients with a history of other malignancies
were not excluded, because PC is most often determinative
for the prognosis. BG could not confirm tumor resection
and was only used in descriptive statistics in Table S2
(Supplementary). SLO and UA were not included in
analyses of neo-ACT, because no information was avail-
able. CAT(E) and UA were not included in analyses of
ACT, because no information was available.
Statistical Analyses
Statistical analyses were performed using SPSS Inc. for
Windows (version 23.0). Numerical data are reported as
mean [standard deviation (SD)] and compared using the
one-way ANOVA test. Categorical data are reported as
absolute numbers (percentages) and compared using the
Chi square test. Multivariable logistics regression analyses
(adjusted for sex, age group, and stage) where performed
for neo-ACT, ACT, and 90-day mortality. Kaplan–Meier
curves, log-rank tests, and multivariable Cox regression
analyses (adjusted for sex, age group, stage) where used to
compare OS. For multivariable comparisons between reg-
istries, BE (national) and CAT(E) (regional) were used as
reference groups (first in alphabetic order). For reasons of
bias, comparisons were performed separately per registry
type: national, regional, and single-center registries. To
assess the risk of missing data bias, sensitivity analyses
were conducted by adding patients with ‘‘unknown’’ stage
to the original analyses. To assess the influence of 90-day
mortality on the use of ACT, multivariable sensitivity
analysis was performed with 90-day mortality as covariate.
To assess the influence of use of (neo-)ACT on OS, mul-
tivariable sensitivity analysis was performed with
(neo-)ACT as covariates. The original results were con-
sidered robust if the sensitivity analyses showed similar
results. P\ 0.05 was considered statistically significant for
all analyses.
RESULTS
Patient and Tumor Characteristics
Figure S1 (Supplementary) illustrates the inclusion of
patients in this study. In total, 2052 patients diagnosed in
2012–2013 underwent tumor resection for pancreatic ade-
nocarcinoma stage I and II were included (Table 1).
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Distribution of males/females was largely comparable
between the registries. The mean (SD) age differed
between the national registries, ranging from 57.5 (11.8)
years in UA to 66.7 (10.0) years in BE, and the regional
registries, 67.4 (9.6) years in CAT(E) and 69.3 (9.2) years
in MU(D). In all registries, stage II patients were the
majority of patients undergoing tumor resection, ranging
from 78.5% (UA) to 98.2% (MIL(I)). Overall, tumors were
most often (73.6%) located in ‘‘head of pancreas’’ and
‘‘pancreatoduodenectomy’’ was performed in majority
(81.2%) of patients, excluding SLO who did not specify
type of resection. Table S2 (Supplementary) shows char-
acteristics of patients for BG, who could not confirm tumor
resection.
Neoadjuvant Chemotherapy
Overall, the use of neo-ACT ranged from 2.8% in NL to
15.5% in MIL(I). There were no differences between the
national and regional registries (Figs. 1a, b).
Multivariable analyses showed differences in odds ratios
(OR) for the use of neo-ACT between the national reg-
istries: patients in NL were less likely to receive neo-ACT
compared with BE (NL: odds ratio [OR] = 0.48, 95%
confidence interval [CI] = 0.29–0.89, P = 0.020; Table 2).
No other predictive factors where identified in the national,
regional, or single-center registries. Sensitivity analyses
with patients with unknown stage added to the multivari-
able analyses showed similar OR.
Adjuvant Chemotherapy
Overall, the use of ACT ranged from 40.5% in
MU(D) to 70.0% in MIL(I). A higher proportion of ACT in
stage II versus stage I was observed in all registries
(Figs. 1c, d). The proportion of patients with stage II
receiving ACT varied between the national registries
(P = 0.017).
Multivariable analyses showed considerable differences
in OR for the use of ACT between the national registries
(Table 2). Patients in NL and SLO were significantly less
likely to receive ACT compared with BE (NL: OR = 0.70,
95% CI = 0.53–0.93, P = 0.012; SLO: OR = 0.32, 95%
CI = 0.19–0.56, P\ 0.001). Furthermore, patients in
ascending age group and patients with stage I were less
likely to receive ACT in the national registries. In the
TABLE 1 Patient and tumor characteristics
Registry
National P value Regional P value Single
center
Belgium
(N = 469)
The
Netherlands
(N = 645)
Slovenia
(N = 73)
Ukraine
(N = 214)
Catalonia
(N = 210)
Munich
(N = 331)
Milan
(N = 110)
N % N % N % N % N % N % N %
Sex
Male 256 54.6% 329 51.0% 39 53.4% 130 60.7% 0.098 116 55.2% 161 48.6% 0.135 60 54.5%
Female 213 45.4% 316 49.0% 34 46.6% 84 39.3% 94 44.8% 170 51.4% 50 45.5%
Age
Mean (SD) 66.7 (10.0) 66.0 (9.0) 65.6 (10.2) 57.5 (9.8) \ 0.001 67.4 (9.6) 69.3 (9.2) 0.020 68.3 (9.8)
Stage
I 70 14.9% 65 10.1% 6 8.2% 46 21.5% \ 0.001 20 9.5% 10 3.0% 0.001 2 1.8%
II 399 85.1% 580 89.9% 67 91.8% 168 78.5% 190 90.5% 321 97.0% 108 98.2%
Location
Head of pancreas 287 61.2% 525 81.4% 56 76.7% 145 67.8% \ 0.001 176 83.8% 252 76.1% \ 0.001 70 63.6%
Body of pancreas 25 5.3% 18 2.8% 8 11.0% 20 9.3% 27 12.9% 16 4.8% 0 0.0%
Tail of pancreas 35 7.5% 47 7.3% 6 8.2% 16 7.5% 7 3.3% 27 8.2% 0 0.0%
Other pancreas 122 26.0% 55 8.5% 3 4.1% 33 15.4% 0 0.0% 36 10.9% 401 36.4%
Type of surgery
Pancreatoduodenectomy 377 80.4% 571 88.5% 0 0.0% 149 69.6% \ 0.001 200 95.2% 240 72.5% \ 0.001 70 63.6%
Other2 92 19.6% 73 11.3% 0 0.0% 65 30.4% 10 4.8% 91 27.5% 40 36.4%
Unknown 0 0.0% 1 0.2% 733 100.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
1Includes tumours from body and tail of pancreas
2Other types of pancreatectomy (e.g., total and distal pancreatectomy or enucleation)
3Authors confirmed these patients underwent oncological resections
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regional and single-center registry, patients in age
group[ 75 years also were less likely to receive ACT.
Sensitivity analyses with patients with unknown stage
added to the multivariable analyses showed similar results,
except that in regional and single-center registries each
ascending age group was significantly less likely to receive
ACT. Sensitivity analyses with 90-day mortality as
covariate in the multivariable analyses showed similar OR.
Ninety-Day Mortality
Ninety-day mortality differed between the national
registries (P = 0.001; Fig. 2). UA (13.6%) and
MU(D) (8.5%) had the highest 90-day mortality in the
national and regional registries respectively, whereas
overall MIL(I) (single-center registry) had the lowest
90-day mortality (0.9%).
Multivariable analyses showed considerable differences
in OR for 90-day mortality between the national registries
(Table 2). Compared with BE, patients in NL had lower
90-day mortality (OR = 0.56, 95% CI = 0.35–0.89,
P = 0.014) and patients in UA (OR = 2.21, 95% CI =
1.23–3.68, P = 0.007) had higher 90-day mortality.
Female and the younger age group were significant pro-
tective factors for 90-day mortality in the national
registries. No predictive factors were identified in the
regional registries. Multivariable analyses in the single-
center registry was not possible due to a low number of
events. Sensitivity analyses with patients with unknown
stage added to the multivariable analyses showed similar
OR.
Overall Survival
OS was significantly different in the national
(P\ 0.001) and regional (P = 0.005) registries (Fig. 3a,
c). In multivariable analysis for OS in the national reg-
istries, UA showed a significantly different OS compared
with BE (hazard ratio (HR) = 2.29, 95% CI = 1.83–2.85,
P\ 0.001; Table 2). Female sex was a significant protec-
tive factors for OS (HR = 0.77, 95% CI = 0.68–0.87,
P\ 0.001). Patients in each ascending age group
(65–75 years: HR = 1.16, 95% CI = 1.01–1.34,
P = 0.040;[ 75 years: HR = 1.75, 95% CI = 1.44–2.12,
P\ 0.001) and stage II (HR = 1.86, 95% CI = 1.69–2.31,
P\ 0.001) showed worse OS. In the regional registries,
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FIG. 1 Neoadjuvant and adjuvant chemotherapy per registry in a neoadjuvant chemotherapy in stage I, b neoadjuvant chemotherapy in stage II,
c adjuvant chemotherapy in stage I, d adjuvant chemotherapy in stage II
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MU(D) showed a significantly different OS compared with
CAT(E) (HR = 1.29, 95% CI = 1.03–1.61, P = 0.026).
Age group[ 75 years was a significant factor with worse
OS compared to age group\ 65 years (HR = 1.43, 95%
CI = 1.08–1.90, P = 0.013), whereas the age group
65–75 years was not. Also, sex and stage were not signif-
icant factors for OS. In the single-center registry, only the
age group[ 75 years was a borderline significant factor
with worse OS compared with the age group\ 65 years
(HR = 1.62, 95% CI = 0.92–2.85, P = 0.094).
In addition, median (95% CI) survival of patients who
received ACT was: 20.1 (18.5–21.7) months in the
national-, 19.0 (15.6–22.4) months in the regional-, and
30.0 (24.4–35.6) months in the single center registries and
median (95% CI) survival of ACT naı¨ve patients: 12.1
(10.3–13.9) months in the national-, 14.0 (11.2–16.8)
months in the regional-, and 19.0 (11.1–26.8) months in the
single center registries, although a direct comparison is not
possible.
Sensitivity analyses with patients with unknown stage
added to the multivariable analyses showed similar HR.
Sensitivity analyses with ACT added to the multivariable
analyses showed similar HR.
DISCUSSION
The main purpose of this study was to describe and
compare (neo–)ACT and outcomes of patients who
underwent tumor resection for stage I and II pancreatic
adenocarcinoma in the EURECCA consortium. There were
some differences in the use of neo-ACT. Although the
ESMO guidelines—during the study period and most
recently—recommended the use of ACT, variations were
observed in OR for ACT usage between national reg-
istries.6 Also, large variations in 90-day mortality and OS
were observed between the registries included in this study.
Previous studies from the EURECCA consortium
showed variations in the use of chemo(radiation)therapy in
colon, rectal, and breast cancer patients.17–19 The observed
variations in neo-ACT, but mainly ACT, between the
registries in this study are in concordance with a recent
large-scale international study of resected PC patients.20 A
possible explanation for the variations can be differences in
adherence to (inter)national guidelines.18,19 Also, cultural,
socioeconomic, and healthcare differences may play a role
in the use of (neo-)ACT.21–23 The observation that few
patients received neo-ACT was probably due to the state-
ment by the ESMO guidelines (during the study period)
that neo-ACT should be used in clinical trial settings.6
Clinical trials are more easily accessible in specialized
centers, which explains the greater use of neo-ACT in the
(specialized) single-center registry compared with the
national and regional registries. A recent meta-analysis has
shown the benefit of neo-ACT over upfront surgery.24 An
interesting international comparison would be how these
results are implemented in more recent practice. A com-
plicated postoperative course can delay or omit the use of
ACT.25 In a sensitivity analyses with 90-day mortality
added to the multivariable analyses for the use of ACT, we
confirmed that differences in 90-day mortality were not of
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influence on the differences in the use of ACT between the
registries. The use of ACT decreased per ascending age
group and patients in the age group[ 75 years showed a
significant worse OS in multivariable analyses in the
national, regional, and single-center registries. As previ-
ously investigated, elderly patients are at higher risk of
postoperative complications.26 Although centralization
improved outcome of pancreatic surgery in elderly patients
in a recent study, further research is needed to gain
knowledge on this matter.27
Variations in 90-day mortality were observed between
the national registries, even after adjustment for sex, age
group, and stage. Multiple studies have shown a lower
postoperative mortality after pancreatic surgery in high-
compared with low-volume hospitals.28,29 In our study this
could not be assessed, because the annual hospital volumes
were not available. Nonetheless, BE and MU(D) showed a
high 90-day mortality and centralization of pancreatic
surgery was not (yet) implemented over there during the
study period. Caution has to be taken with this statement as
detailed information about perioperative treatment, likely
to affect 90-day mortality, was not available.
This study showed a better survival in patients receiving
ACT compared with naı¨ve patients in the national, regio-
nal, and single-center registries. This can be explained by
confounding by indication (fit patients with a good prog-
nosis are generally more likely to receive ACT), and
therefore a justifiable comparison is not possible. The
recent ESPAC-4 trial (2017) showed a significant better
survival for patients treated with adjuvant gemcitabine and
capecitabine compared with gemcitabine alone (28.0 (95%
CI = 23.5–31.5 months vs. 25.5 (95% CI = 22.7–27.9)
months) after resection for PC.7 Considering the random-
ized ESPAC-trial has strict inclusion criteria (e.g., full
recovery after surgery, creatinine clearance C 50 mL/min)
and our study is mainly population-based, the results are
largely comparable. Still, direct comparison is hampered
by the differences in study design. In a sensitivity analyses
with (neo-)ACT added to the multivariable analyses for
OS, we confirmed that differences in ACT were not of
influence on the differences in OS between the registries.
Definite conclusions cannot be drawn from this sensitivity
analysis, because immortal time bias and confounding by
indication cannot be ruled out.
Our study has several limitations. First, caution has to be
taken with interpretation of the results as differences in
(unmeasured) patient characteristics (e.g., patient selection
for tumor resection) might have been of influence. Nev-
ertheless, analyses were adjusted for important factors (sex,
age group, stage) and still showed differences between the
registries. Second, due to inherent differences between
national, regional, and single-center registries, which also
explain the observed inter-registry-type variations,
analyses had to be performed separately per registry type
and lowered the statistical power (e.g., multivariable
analyses for 90-day mortality was not possible in the sin-
gle-center registry). Third, due to missing data this study
excluded some patients (e.g., unknown stage or tumor
resection) and registries (e.g., SLO and UA did not provide
data on neo-ACT, CAT(E), and UA did not provide data on
ACT and the dataset from BG could not confirm tumor
resection) from certain analyses. A possible explanation for
this is that the provided datasets may originally have been
established for other intentions (e.g., Cancer Registry or
Clinical/Surgical Audit) and thus focused on completeness
of certain (other) variables. Although most included reg-
istries are surgically driven and therefore very comparable,
this probably introduced missing data bias.30 Sensitivity
analyses with patients with unknown stage added to the
analyses confirmed the robustness of the results of this
study. Still, variables, such as stage and tumor resection,
are pivotal when investigating treatment and outcome in
cancer patients. Future registration should focus on com-
pleteness and uniform use of definitions as previously
stated by other member of the EURECCA consortium.13,17
Nonetheless, this study is the first to describe and compare
(neo-)ACT and outcome of patients undergoing tumor
resection for pancreatic adenocarcinoma stage I and II in
eight different European registries.
CONCLUSIONS
The results of this study give a clear insight in the
clinical practice of the partners in the EURECCA Pancreas
consortium. Overall, the variations illustrate the difference
in implementation of universally accepted and used
guidelines for treatment of pancreatic adenocarcinoma
stage I and II. The differences in the use of (neo-)ACT and
outcome provide us the chance to further investigate the
best practices. Moreover, the EURECCA Pancreas con-
sortium underlines the need for uniform registration as
international comparisons will become increasingly
important pillars of international guidelines.
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